Physician profile
Sarah Ann Mcgee
NPI 1396521845
$5,394.25
in general payments reported to CMS, 2019-2025
23 companies · $4,424 in 2025
The $4,424 reported for 2025 was more than what 98% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $970 · 2025: $4,424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,369 · Education: $25.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,368.92 |
| Education | $25.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,145.90 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $801.50 | 2024-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $591.10 | 2024-2025 | Tremfya, Stelara, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $409.95 | 2024-2025 | Xifaxan |
| Lilly USA, LLC | $354.36 | 2024-2025 | Omvoh |
| Madrigal Pharmaceuticals | $342.89 | 2024-2025 | Rezdiffra, Resmetirom |
| Regeneron Healthcare Solutions, INC. | $319.18 | 2024-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $247.44 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $238.97 | 2024-2025 | Ibsrela |
| Novo Nordisk INC | $214.20 | 2025 | Wegovy |
| Genzyme Corporation | $128.33 | 2025 | |
| Gilead Sciences, INC. | $123.00 | 2025 | |
| Pfizer INC. | $93.55 | 2025 | |
| Qol Medical, LLC | $90.33 | 2024-2025 | Sucraid, Sucraid |
| Celltrion USA INC. | $83.12 | 2024-2025 | Zymfentra, Vegzelma |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $59.93 | 2025 | Iqirvo |
| Mallinckrodt Hospital Products INC. | $33.62 | 2025 | Terlivaz |
| Sandoz INC. | $25.74 | 2025 | Hyrimoz |
| Aimmune Therapeutics, INC. | $23.11 | 2025 | Zenpep |
| Braintree Laboratories, INC. | $21.65 | 2025 | Sutab, Suflave |
| Teleflex LLC | $16.45 | 2025 | Titan Sgs Bailout Chuck |
| Ironwood Pharmaceuticals, INC | $14.99 | 2025 | |
| Ferring Pharmaceuticals INC. | $14.94 | 2025 | Rebyota |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Mcgee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.